1. Scrip
  2. >>Business

Novartis India MD On Scalable Digital Solutions, Balancing Work-Life Mix Amid COVID-19

 
• By Anju Ghangurde

Novartis India chief outlines how the company is navigating the challenging business environment amid the coronavirus pandemic, including for its for-profit social business. Digital solutions are a key part of these efforts and the executive offers advice for those struggling to balance the work-life mix in these testing times.

Sanjay Murdeshwar
Novartis India MD Sanjay Murdeshwar • Source: Novartis India

When ex-AstraZeneca PLC executive Sanjay Murdeshwar took over as managing director of Novartis India Ltd. in June 2019, few would have ever imagined that unprecedented change, and upheaval for some, in life routines and business operations lay in store just months down the line as the coronavirus pandemic spread across the world. (Also see "Novartis India's New Chief Has A Full Plate" - Scrip, 17 June, 2019.)

Pharma has since been adjusting its operational aspects to align with the "new normal", though Novartis AG has maybe been better placed than some peers, given its early thrust into digital areas as one of its key strategic priorities

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.